Predictive biochemical-markers for the development of brain metastases from lung cancer: Clinical evidence and future directions

Cancer Epidemiology

Volumn 37, Issue 5, 2013, Pages 703-707

  Huang, Qian ^a   Ouyang, Xuenong ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

Author keywords

Brain metastases; Circulating markers; Lung cancer; Pathologic markers; Predictive value

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MICRORNA; NERVE CELL ADHESION MOLECULE; PROTEIN S 100; SMAD6 PROTEIN; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

BRAIN METASTASIS; GENE MUTATION; GENOTYPE; INCIDENCE; LUNG CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BRAIN METASTASES; CIRCULATING MARKERS; LUNG CANCER; PATHOLOGIC MARKERS; PREDICTIVE VALUE;

BRAIN NEOPLASMS; HUMANS; LUNG NEOPLASMS; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884144910     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2013.06.003     Document Type: Review

References (52)

1. Saad A.G., Yeap B.Y., Thunnissen F.B., Pinkus G.S., Pinkus J.L., Loda M., et al. Immuno-histochemical markers associated with brain metastases in patients with non-small cell lung carcinoma. Cancer 2008, 113(8):2129-2138.
2. Patel S., Macdonald O.K., Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 2009, 115(4):842-850.
3. Slotman B., Faivre-Finn C., Kramer G., Rankin E., Snee M., Hatton M., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007, 357(7):664-672.
4. Gore E.M., Bae K., Wong S.J., Sun A., Bonner J.A., Schild S.E., et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011, 29(3):272-278.
5. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics 2009, 6(3):465-477.
6. Fidler I.J. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011, 21(2):107-112.
7. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fuku-mura D., et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA 2010, 107(50):21677-21682.
8. Preusser M., Capper D., Ilhan-Mutlu A., Berghoff A.S., Birner P., Bartsch R., et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012, 123(2):205-222.
9. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain meta-stases-translation to new therapies. Nat Rev Clin Oncol 2011, 8(6):344-356.
10. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436(7050):518-524.
11. Chiang A.C., Massague J. Molecular basis of metastasis. N Engl J Med 2008, 359(26):2814-2823.
12. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):175-180.
13. Li Z., Lu J., Zhao Y., Guo H. The retrospective analysis of the frequency of EGFR mutations and efficacy of gefitinib in NSCLC patients with brain metastases. J Clin Oncol 2011, 29. (Suppl. abstr. e18065).
14. Heon S., Yeap B.Y., Britt G.J., Costa D.B., Rabin M.S., Jackman D.M., et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010, 16(23):5873-5882.
15. Eichler A.F., Kahle K.T., Wang D.L., Joshi V.A., Willers H., Engelman J.A., et al. EGFR mutation status and survival after diagnosis of brain metastasis in non small cell lung cancer. Neuro Oncol 2010, 12(11):1193-1199.
16. Sekine A., Kato T., Hagiwara E., Shinohara T., Komagata T., Iwasawa T., et al. Metastatic brain tumors from non small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. Lung Cancer 2012, 77(1):64-69.
17. Yang P., Kulig K., Boland J.M., Erickson-Johnson M.R., Oliveira A.M., Wampfler J., et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012, 7(1):90-97.
18. Preusser M., Berghoff A.S., Ilhan-Mutlu A., Magerle M., Dinhof C., Widhalm G., et al. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. Lung Cancer 2013, Feb 27 [Epub ahead of print].
19. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickhardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive non small cell lung cancer. Cancer 2012, 118(18):4502-4511.
20. Yoo J., Lee S.H., Lym K.I., Park S.Y., Yang S.H., Yoo C.Y., et al. Immunohistochemical expression of DCUN1D1 in non-small cell lung carcinoma: its relation to brain metastasis. Cancer Res Treat 2012, 44(1):57-62.
21. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16(11):2927-2931.
22. Wald O., Izhar U., Amir G., Kirshberg S., Shlomai Z., Zamir G., et al. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation. J Thorac Cardiovasc Surg 2011, 141(6):1503-1512.
23. Lee Y.L., Kuo W.H., Lin C.W., Chen W., Cheng W.E., Chen S.C., et al. Association of genetic polymorphisms of CXCL12/SDF1 gene and its receptor, CXCR4, to the susceptibility and prognosis of non-small cell lung cancer. Lung Cancer 2011, 73(2):147-152.
24. Paratore S., Banna G.L., D'Arrigo M., Saita S., Iemmolo R., Lucenti L., et al. CXCR4 and CXCL12 immunoreactivities differentiate primary non-small-cell lung cancer with or without brain metastases. Cancer Biomark 2011, 10(2):79-89.
25. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 2006, 12(17):5018-5022.
26. Chen G., Liu X.Y., Wang Z., Liu F.Y. Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg 2010, 37(3):546-551.
27. Sun M., Behrens C., Feng L., Ozburn N., Tang X., Yin G., et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009, 15(15):4829-4837.
28. Hiratsuka S., Duda D.G., Huang Y., Goel S., Sugiyama T., Nagasawa T., et al. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci USA 2011, 108(1):302-307.
29. Serres S., Soto M.S., Hamilton A., McAteer M.A., Carbonell W.S., Robson M.D., et al. Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci USA 2012, 109(17):6674-6679.
30. Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008, 26(4):462-469.
31. Mueller W.C., Spector Y., Edmonston T.B., St Cyr B., Jaeger D., Lass U., et al. Accurate classification of metastatic brain tumors using a novel microRNA-based test. Oncologist 2011, 16:165-174.
32. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 2011, 6(e17745):18.
33. Chen L.T., Xu S.D., Xu H., Zhang J.F., Ning J.F., Wang S.F. MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration: invasion and tumor angiogenesis. Med Oncol 2012, 29(3):1673-1680.
34. Arora S., Ranade A.R., Tran N.L., Nasser S., Sridhar S., Korn R.L., et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011, 129(11):2621-2631.
35. Szafranska A.E., Davison T.S., Shingara J., Doleshal M., Riggenbach J.A., Morrison C.D., et al. Accurate molecular characterization of formalin-fixed: paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn 2008, 10(5):415-423.
36. Andrews J.L., Kim A.C., Hens J.R. The role and function of cadherins in the mammary gland. Breast Cancer Res 2012, 14(1):203.
37. Hui L., Zhang S., Dong X., Tian D., Cui Z., Qiu X. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS ONE 2013, 8(4):e62171.
38. Zhao J.Q., Sun F.J., Liu S.S., Yang J., Wu Y.Q., Li G.S., et al. Expression of connexin 43 and E-cadherin protein and mRNA in non-small cell lung cancers in Chinese patients. Asian Pac J Cancer Prev 2013, 14(2):639-643.
39. Canel M., Serrels A., Frame M.C., Brunton V.G. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci 2013, 126(Pt 2):393-401.
40. Grinberg-Rashi H., Ofek E., Perelman M., Skarda J., Yaron P., Hajdúch M., et al. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 2009, 15(5):1755-1761.
41. Yoo J.Y., Yang S.H., Lee J.E., Cho D.G., Kim H.K., Kim S.H., et al. E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer: and its regulation by pioglitazone in a preclinical model. J Neurooncol 2012, 109(2):219-227.
42. Shabani H.K., Kitange G., Tsunoda K., Anda T., Tokunaga Y., Shibata S., et al. Immunohistochemical expression of E-cadherin in metastatic brain tumors. Brain Tumor Pathol 2003, 20(1):7-12.
43. Lee D.S., Kim Y.S., Jung S.L., Lee K.Y., Kang J.H., Park S., et al. The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumour Biol 2012, 33(4):1065-1073.
44. Arrieta O., Saavedra-Perez D., Kuri R., Aviles-Salas A., Martinez L., Mendoza-Posada D., et al. Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis of brain metastases. BMC Cancer 2009, 9:119.
45. Kanner A.A., Marchi N., Fazio V., Mayberg M.R., Koltz M.T., Siomin V., et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003, 97(11):2806-2813.
46. Vogelbaum M.A., Masaryk T., Mazzone P., Mekhail T., Fazio V., McCartney S., et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer 2005, 104(4):817-824.
47. Marchi N., Mazzone P., Fazio V., Mekhail T., Masaryk T., Janigro D., et al. A serum marker of brain metastases in lung cancer patients. Cancer 2008, 112(6):1313-1324.
48. Liu H., Kato Y., Erzinger S.A., Kiriakova G.M., Qian Y., Palmieri D., et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer 2012, 12:583.
49. Husmann K., Arlt M.J., Muff R., Langsam B., Bertz J., Born W., et al. Matrix Metalloproteinase 1 pro-motes tumor formation and lung metastasis in an intratibial injection osteosarcoma mouse model. Biochim Biophys Acta 2013, 1832(2):347-354.
50. Karnezis T., Shayan R., Caesar C., Roufail S., Harris N.C., Ardipradja K., et al. VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. Cancer Cell 2012, 21(2):181-195.
51. Li B., Wang C., Zhang Y., Zhao X.Y., Huang B., Wu P.F., et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis. Oncogene 2012, Jul 16 [Epub ahead of print].
52. Li Q., Wu H., Chen B., Hu G., Huang L., Qin K., et al. SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer. PLoS ONE 2012, 7(12):e51713.